Baotou Dongbao Bio-Tech Co., Ltd. Class A

Baotou Dongbao Bio-Tech Co., Ltd. Class A

SSZSE:300239
4.73
CNY
-0.05
(-1.05%)
0.10EPS
52.56P/E
3.24BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A carries a market capitalization of 3.24B, placing it among publicly traded companies globally. Its enterprise value stands at 3.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.24B
Enterprise Value3.35B

Share Statistics

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A has 593.62M shares outstanding.

Shares Outstanding593.62M

Valuation Ratios

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 52.56. The price-to-sales ratio is 3.83, and the price-to-book ratio stands at 1.83.

PE Ratio52.56
PS Ratio3.83
PB Ratio1.83
P/TBV Ratio1.98

Enterprise Valuation

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A trades at an EV/EBITDA multiple of 51.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 51.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.35B versus a market cap of 3.24B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.01
EV / EBITDA51.90
EV / EBIT51.90

Financial Position

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A maintains a current ratio of 4.08, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.33, indicating elevated leverage, while an interest coverage ratio of 9.01 demonstrates adequate ability to service its debt obligations.

Current Ratio4.08
Quick Ratio1.32
Debt / Equity26.33
Debt / EBITDA7.23
Interest Coverage9.01

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A posted a return on equity (ROE) of 3.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.62 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.02, useful for judging operating efficiency across full business cycles. The company generates approximately 496,798.25 in revenue per employee across its workforce of 1,681.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times Baotou Dongbao Bio-Tech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.50
Return on Assets (ROA)2.35
Return on Invested Capital (ROIC)2.62
Return on Capital Employed (ROCE)3.02
Revenue Per Employee496,798.25
Employee Count1,681.00
Inventory Turnover1.58

Taxes

CNY

Over the twelve months ended September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A recorded 5.90M in income tax expense. That works out to an effective tax rate of 8.85, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 66.73M, leaving 60.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax5.90M
Effective Tax Rate8.85

Stock Price Statistics

CNY

As of the close on November 17, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A's stock has declined approximately 20.37% over the past 52 weeks. The 50-day moving average sits at 5.04, while the 200-day moving average is 5.33.

52-Week Price Change-20.37%
50-Day Moving Average5.04
200-Day Moving Average5.33

Income Statement

CNY

Over the twelve months ended September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A generated 835.12M in revenue and converted that into 60.83M in net income, yielding earnings per share of 0.10. EBITDA reached 64.49M, while operating income came in at 85.26M.

Revenue835.12M
Gross Profit184.07M
Operating Income85.26M
Pretax Income66.73M
Net Income60.83M
EBITDA64.49M
EBIT64.49M
Earnings Per Share (EPS)0.10

Balance Sheet

CNY

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A holds 360.81M in cash and equivalents against 466.37M in total debt, resulting in a net debt position of 104.40M. Total book value stands at 1.77B, with working capital of 843.59M providing operational flexibility.

Cash & Cash Equivalents360.81M
Total Debt466.37M
Net Debt104.40M
Equity (Book Value)1.77B
Book Value Per Share2.98
Working Capital843.59M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-177.25M

Margins

Over the twelve months ended September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A posted a gross margin of 22.04, reflecting its pricing power and cost economics. The operating margin of 10.21 and net profit margin of 7.28 provide insight into operational efficiency.

Gross Margin22.04
Operating Margin10.21
Pretax Margin7.99
Profit Margin7.28
EBITDA Margin7.72

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of 20.61 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.86, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Baotou Dongbao Bio-Tech Co., Ltd. Class A shareholders.

Dividend Per Share0.02
Payout Ratio20.61
Shareholder Yield1.86

Stock Splits

Baotou Dongbao Bio-Tech Co., Ltd. Class A's most recent stock split took place on May 31, 2016 with a 1:2 split ratio.

Last Split Date5/31/2016
Split Ratio1:2

Scores

As of September 30, 2026, Baotou Dongbao Bio-Tech Co., Ltd. Class A has an Altman Z-Score of 3.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.46